What is Survodutide?
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Unlike single GLP-1 agonists, survodutide simultaneously activates two complementary metabolic pathways: the satiety and insulin secretion pathway (GLP-1) and the energy expenditure and hepatic metabolism pathway (glucagon).
Its profile positions it as the most promising candidate within the GLP-1/GCGR class for the management of obesity with a hepatic component, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) — a combination affecting a significant fraction of people with metabolic obesity.
It is currently in advanced clinical development under the SYNCHRONIZE program, which includes the SYNCHRONIZE-1, SYNCHRONIZE-2, and SYNCHRONIZE-CVOT (cardiovascular safety) studies.
Dual mechanism of action: GLP-1 + Glucagon
GLP-1 Receptor
- Increases glucose-dependent insulin secretion
- Reduces appetite and caloric intake through central signaling (hypothalamus)
- Slows gastric emptying, prolonging satiety
- Improves glycemic control without intrinsic hypoglycemia risk
Glucagon Receptor (GCGR)
- Increases hepatic energy expenditure and fatty acid beta-oxidation
- Reduces triglyceride synthesis and accumulation in the liver
- Produces a direct effect on hepatic lipolysis — a mechanism particularly relevant in NAFLD/NASH
- Increases thermogenesis and basal caloric expenditure
The balance between these two receptors is key to survodutide’s favorable metabolic profile. Glucagon alone would be hyperglycemic; combined with GLP-1 agonism, the net result is improved glycemic control with accelerated fat loss — including hepatic fat.
Clinical results (Phase 2)
The pivotal Phase 2 study published in Lancet Diabetes & Endocrinology (Le Roux et al., 2024) included participants with obesity (BMI ≥30) over 46 weeks of active treatment:
- Body weight loss: 12.5% to 14.9% depending on assigned dose
- Reduction of hepatic biomarkers: statistically significant improvements in ALT, AST, and fibrosis markers in participants with hepatic steatosis
- Improvements in lipid profile: reductions in triglycerides and LDL cholesterol
- The NAFLD/NASH subgroup showed additional benefits beyond weight loss per se, consistent with the direct effect of glucagon receptor agonism on the liver
Key differentiator: no other next-generation GLP-1 agent (cagrilintide/semaglutide, retatrutide) has reported comparable specific evidence in liver disease in published trials through 2024.
Escalation protocol — 7 steps
Reconstitution: 10 mg in 2.0 mL bacteriostatic water (BAC) → concentration 5.0 mg/mL
Equivalence: 1 U-100 unit = 50 mcg (0.05 mg)
| Weeks | Dose (mg) | Volume (mL) | U-100 Units | Recommended syringe |
|---|---|---|---|---|
| 1–2 | 0.6 mg | 0.12 mL | 12 u | 1 mL U-100 |
| 3–4 | 1.2 mg | 0.24 mL | 24 u | 1 mL U-100 |
| 5–6 | 1.8 mg | 0.36 mL | 36 u | 1 mL U-100 |
| 7–8 | 2.4 mg | 0.48 mL | 48 u | 1 mL U-100 |
| 9–10 | 3.6 mg | 0.72 mL | 72 u | 1 mL U-100 |
| 11–12 | 4.8 mg | 0.96 mL | 96 u | 1 mL U-100 |
| 13+ | 6.0 mg | 1.20 mL | 120 u | ⚠️ See note below |
Route of administration: subcutaneous (abdomen, anterior thigh, or arm). Weekly injection, same time of day.
Storage
- Lyophilized (powder): store at ≤–20 °C, protected from light
- Reconstituted: 2–8 °C (refrigerated), protected from light, use within 28 days
- Do not re-freeze once reconstituted
- Inspect for particles before each use; discard if solution appears cloudy
Reported adverse effects
Adverse effects are primarily gastrointestinal and follow a dose-dependent pattern, most pronounced during the escalation phase:
- Nausea (most common): typically within the first 48–72 h after a dose step-up
- Vomiting
- Diarrhea
- Constipation
- Appetite reduction (expected effect, not adverse in a weight loss context)
Management: The gradual 7-step titration over 12 weeks is specifically designed to minimize GI intolerance. If symptoms are intense at a given step, the current dose may be held for one or two additional weeks before advancing.
Important note: Maintenance dose and syringes
The maintenance dose of 6.0 mg (120 U-100 units) equals 1.20 mL at the standard 5.0 mg/mL concentration. This volume exceeds the capacity of a standard 1 mL U-100 insulin syringe.
Options for the maintenance dose:
- 1–3 mL Luer-lock syringe: allows the full volume to be administered in a single injection
- Split into two subcutaneous injections: 0.60 mL each, at separate sites, on the same day
Planning for adequate syringe supply before reaching week 13 is part of responsible protocol management.
Regulatory status
Survodutide is in Phase 3 clinical development under the SYNCHRONIZE program (Boehringer Ingelheim):
- SYNCHRONIZE-1: efficacy in weight reduction
- SYNCHRONIZE-2: efficacy with metabolic comorbidities
- SYNCHRONIZE-CVOT: long-term cardiovascular safety
It is not approved by the FDA, EMA, or any regulatory agency. Its availability outside authorized clinical trials is for research use only.
Research use only. Not medical advice. This content is for educational and informational purposes only. Survodutide is not approved by the FDA or any health authority. This does not constitute a diagnosis, prescription, or replacement for evaluation by a qualified healthcare professional. Any experimental use must be supervised by competent medical personnel and within the legal framework of the applicable jurisdiction.
Reported protocol (research reference)
| Vial sizes | 10 mg |
|---|---|
| Reported dose | Weekly escalation over 7 steps (12 weeks). Maintenance dose: 6.0 mg/week (120 U-100 units). Reconstitution: 10 mg in 2.0 mL bacteriostatic water → 5.0 mg/mL (1 U-100 unit = 50 mcg). |
| Half-life | ~7 days (weekly dosing) |
| FDA status | Investigational |